A trial looking at sacituzumab tirumotecan for breast cancer that has spread (MK-2870-010)

This trial is looking at sacituzumab tirumotecan on its own or with pembrolizumab for people with breast cancer. It is comparing this to standard chemotherapy.

It is for people whose breast cancer:

• has spread into surrounding tissues or to another part of the body

• has a small number or no receptors for HER2. This is HER2 negative breast cancer.

• has a lot of hormone receptors. This is hormone positive breast cancer.